DRUG SUSCEPTIBITITY OF MYCOBSCTERIA AVIUM-INTRACELLULARE COMPLEX (МАС)
Abstract
We detected MICs for the line of the drugs using for the treatment of mycobacterisises caused by mycobacteria of avium-intracellulare complex (МАС). Our MICs meanings were similar (but not always identical) to those determined by other methods.
Mycobacteria of the МАС were susceptible in most cases to amikacin, clarithromycin, moxifloxacin, rifabutin, and resistant to other drugs located on the SlowMyco Sensititre® panel. At the same time, a number of strains with intermediate sensitivity/resistance were determined for a number of drugs for which most strains were resistant. Certain differences in drug sensitivity of M. avium and M. intracellulare species were also revealed. Both of these facts must be considered when prescribing chemotherapy.
About the Authors
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. N. Khachaturiants
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
Yu. D. Mikhaylova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
G. E. Freiman
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
L. D. Guntupova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
A. O. Chizhova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Андреевская С.Н., Ларионова Е.Е., Смирнова Т.Г., Андриевская И.Ю., Киселева Е.А., Черноусова Л.Н. Лекарственная чувствительность медленнорастущих нетуберкулезных микобактерий // Туберкулез и болезни легких. – 2016. – № 4. – С. 43-50.
2. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы. – М.: МНПЦБТ, 2014. – 254 с.
3. Методология и организация доказательных научно-медицинских исследований во фтизиатрии / Под ред. Васильевой И.А. – М.: ООО «НЬЮ ТЕРРА», 2017. – 176 с.
4. Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса, 2005. – 224 с.
5. Abuali M.M., Katariwala R., LaBombardi V.J. A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31 (5). – P. 835-839.
6. Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. – P. 1749-1752.
7. Brown-Elliott B., Crist C., Mann L. et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria // Antimicrob Agents Chemother. – 2003. – Vol. 47. – N. 5. – P. 1736-1738.
8. Brown-Elliott B., Wallace R. Infections caused by nontuberculous mycobacteria // In: Principles and Practice of Infectious Disease / Ed. by Mandell G.). – 2005. – Vol. 2. – P. 2909–2916.
9. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
10. Chazel M., Marchandin H., Keck N. et al. Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates // Ann. Clin. Microbiol. Antimicrob. – 2016. –- Vol. 15. – P. 30.
11. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard: 2nd ed. CLSI document M24-A2. – Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный ресурс]. URL: https://www.clsi.org/media/1463/m24a2_sample.pdf. (Дата обращения 01.06.2018).
12. Daley C. Mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 1-22.
13. Deshpande D., Gumbo T. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium // Future Microbiol. – 2011. – Vol. 6. – N. 4. – P. 433-439.
14. Duan H, Liang Q, Chu N, et al. Macrolide and linezolid susceptibility testing for Mycobacterium intracellulare isolates// - 2014 - Vol. 37. – N. 4. – P. 266-269.
15. Falkinham J. Current epidemiologic trends of the nontuberculous mycobacteria (NTM)// Curr. Environ. Health. Rep. – 2016. – Vol. 3. – N. 2. – P. 161-167.
16. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – P. 243-251.
17. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – P. 367-416.
18. Hall L., Jude K. P., Clark S.L. et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis сomplex against firstand second-line agents //J. Clin. Microbiol. – 2012. – Vol. 50. – N. 11. – P. 3732-3734.
19. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections // CRC Press. Boca Raton Ann Arbor Boston. London, 2000. – P. 212.
20. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. in Respir. Crit. Care Med. – 2004. – Vol. 25. – N. 3. – P. 283-295.
21. Hombach M., Somoskövi A., Hömke R. et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST // Int. J. Med. Microbiol. – 2013. – Vol. 303. – N. 5. – P. 270-276.
22. Horsburgh C., Mason U., Heifets L. et al. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – N. 2. – P. 418-421.
23. Lee J., Armstrong D., Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 11-18.
24. Moon S., Park H., Kim S. et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease // Antimicrob. Agents. Chemother. – 2016. – Vol. 60. – N. 11. – P. 6758-6765.
25. Ryu Y., Koh W., Daley C. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives // Tuberc. Respir. Dis. (Seoul). – 2016. – Vol. 79. – N. 2. – P. 74-84.
26. Slany M., Ulmann V., Slana I. Avium mycobacteriosis: still existing threat to humans // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33. – N. 3. – P. 347-358.
27. Schön T., Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints // Int. J. Infect. Dis. – 2017. – Vol. 55. – P. 122-124.
28. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. – Vol. 45. – P. 123-134.
29. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – P. 906-910.
30. van Ingen J. Diagnosis of nontuberculous mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 103-109.
31. van Ingen J., Kuijper E. Drug susceptibility testing of nontuberculous mycobacteria // Future Microbiol. – 2014. – Vol. 9. – N. 9. – P. 1095-1110.
32. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – P. 1209-1215.
33. Xu H., Jiang R., Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33. – N. 3. – P. 347-358.
34. Yeung M., Khoo E., Brode S. Health-related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review // Respirology. – 2016. – Vol. 21. – N. 6. – P. 1015-1025.
Review
For citations:
Litvinov V.I., Makarova M.V., Khachaturiants E.N., Mikhaylova Yu.D., Freiman G.E., Guntupova L.D., Chizhova A.O. DRUG SUSCEPTIBITITY OF MYCOBSCTERIA AVIUM-INTRACELLULARE COMPLEX (МАС). Tuberculosis and socially significant diseases. 2018;(4):14-19. (In Russ.)
Views:
18
Email this article 